Clinical Overview
Guanfacine extended-release is a non-stimulant medication indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years. It may be used as monotherapy or as adjunctive therapy with stimulant medications for comprehensive ADHD management.
Primary Clinical Applications
Guanfacine XR is particularly valuable for patients who cannot tolerate stimulant medications or require additional symptom control when used with stimulants. It is effective for hyperactivity, impulsivity, and inattention symptoms, with potential benefits for emotional regulation and aggression.
Mechanism and Clinical Benefits
As an alpha-2A adrenergic receptor agonist, guanfacine XR works in the prefrontal cortex to improve working memory and reduce distractibility. Unlike stimulants, it does not affect dopamine directly but modulates norepinephrine signaling to enhance executive function and attention.
Administration and Monitoring
The extended-release formulation allows for once-daily dosing and provides 24-hour symptom control. Blood pressure and heart rate monitoring is essential, particularly during dose titration, as the medication can cause hypotension and bradycardia.
Prescribing Information
Dosing & Administration
ADHD – Children and Adolescents (6-17 years):
- Initial: 1 mg once daily
- Titration: Increase by 1 mg weekly as tolerated
- Target range: 1-4 mg once daily
- Maximum: 4 mg once daily
- Weight-based dosing: 0.05-0.12 mg/kg/day
Administration:
- Take once daily in morning or evening
- May take with or without food
- Swallow tablets whole, do not crush or chew
- Consistent timing each day
Indications
- Treatment of ADHD in children and adolescents (6-17 years)
- May be used as monotherapy or adjunctive with stimulants
Contraindications
- Hypersensitivity to guanfacine or any component
- No absolute contraindications, but caution in cardiovascular disease
Warnings & Precautions
- Hypotension and bradycardia: Monitor blood pressure and heart rate
- Sedation and somnolence: May impair ability to operate machinery
- Syncope: Risk particularly during dose initiation and increases
- Rebound hypertension: Taper gradually when discontinuing
- Cardiac conduction abnormalities: Use caution in patients with heart block
Drug Interactions
- CYP3A4 inducers: May require dose increase up to double
- CYP3A4 inhibitors: Consider dose reduction
- Antihypertensives: Enhanced hypotensive effects
- CNS depressants: Increased sedation risk
Adverse Reactions
Common (≥5%):
- Somnolence, headache, fatigue, upper abdominal pain
- Irritability, hypotension, nausea, lethargy
Cardiovascular:
- Decreased blood pressure and heart rate, syncope
Special Populations
- Renal Impairment: Consider dose reduction in severe impairment
- Hepatic Impairment: Consider dose reduction
- Adults: Not approved for adult ADHD
- Cardiovascular Disease: Monitor closely, may worsen existing conditions
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
